1127238-75-8

Upstream product

• 110-91-8 morpholine 
• 1195781-82-8 5-[13-cyclohexyl-3-methoxy-10-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]-1-cyclopropyl-1H-pyrazole-4-carboxylic acid 
• 1195781-80-6 5-[13-cyclohexyl-3-methoxy-10-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]-1-cyclopropyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1195781-77-1 13-cyclohexyl-6-[1-cyclopropyl-4-(ethoxycarbonyl)-1H-pyrazol-5-yl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid 1,1-dimethylethyl ester 
• 1195781-78-2 13-cyclohexyl-6-[1-cyclopropyl-4-(ethoxycarbonyl)-1H-pyrazol-5-yl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid 
• 1127234-87-0 13-cyclohexyl-10-[(1,1-dimethylethoxy)carbonyl]-3-methoxy-beta-oxo-7H-indolo[2,1-a][2]benzazepine-6-propanoic acid ethyl ester 

Relevant academic research and scientific papers

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.